TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25544635
Drug: Treatment in
Normalized name: Other agents for local oral treatment in ATC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment in posterior region only
Study: 12695241
Drug: Brimonidine twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brimonidine twice a day
Study: 12695241
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of timolol and dorzolamide twice a day
Study: 8690826
Drug: Fluvoxamine maleate
Normalized name: Fluvoxamine Maleate
DrugBank: Fluvoxamine (DB00176)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluvoxamine maleate (50-150 mg/day)
Study: 8690826
Drug: Imipramine (80-240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (80-240 mg/day)
Study: 6137978
Drug: suxamethonium 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: suxamethonium 1 mg X kg‐1 in a single bolus followed by an infusion (group A)
Study: 6137978
Drug: vecuronium 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: vecuronium 0.05 mg X kg‐1 (group B)
Study: 6137978
Drug: vecuronium 0.06
Approvals — FDA: no, EMA: no, PMDA: no
Description: vecuronium 0.06 mg X kg‐1 (group C)
Study: 6137978
Drug: vecuronium 0.07
Approvals — FDA: no, EMA: no, PMDA: no
Description: vecuronium 0.07 mg X kg‐1 (group D)
Study: 26284720
Drug: Liraglutide (3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide (3.0 mg)
Study: 24858158
Drug: Transrectal lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transrectal lidocaine gel (Group I)
Study: 24858158
Drug: Intraprostatic lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraprostatic lidocaine injection with intra rectal gel (Group II)
Study: 15590856
Drug: Triamcinolone injection
Normalized name: triamcinolone Injection
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone injection with nimesulide (200 mg for seven days)
Study: 15590856
Drug: Triamcinolone injection
Normalized name: triamcinolone Injection
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone injection with placebo (for seven days)
Study: 11593959
Drug: Cognitive-behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral treatment (group or individual)
Study: 11593959
Drug: Individual cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual cognitive-behavioral treatment
Study: 9141548
Drug: Oral conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral conjugated equine estrogen (CEE) therapy (0.625 mg daily)
Study: 9141548
Drug: CEE in
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE in combination with medroxyprogesterone acetate (2.5 mg daily)
Study: 9141548
Drug: CEE in
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE in combination with medroxyprogesterone acetate (10 mg daily on days 1-12)
Study: 9141548
Drug: CEE in
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE in combination with micronized progesterone (200 mg daily on days 1-12)
Study: 9141548
Drug: CEE therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE therapy
Study: 3113291
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg butorphanol
Study: 3113291
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg butorphanol
Study: 29553843
Drug: Quince sauce
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quince sauce (QS) 10 mg after meals
Study: 9587554
Drug: Alteplase and
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alteplase and heparin
Study: 7943865
Drug: Combined bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined bolus injection of subnarcotic doses of sodium hydroxybutyrate and sodium thiopental
Study: 3091055
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (ISDN) 10 mg three times daily
Study: 3091055
Drug: Transdermal nitrate
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitrate (TN) one 10 cm2 patch daily
Study: 3091055
Drug: Transdermal nitrate
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitrate (TN)
Study: 25555450
Drug: Single i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single i.v. dose of MAPC (10 million cells/kg)
Study: 25555450
Drug: Once weekly
Normalized name: Actonel 35 4-Week Once Weekly Dosepack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once weekly for up to 5 doses of MAPC (1 or 5 million cells/kg)
Study: 25555450
Drug: MAPC infusions
Normalized name: Multipotent Adult Progenitor Cells (MAPCs)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAPC infusions
Study: 23766098
Drug: Liquid OLE
Normalized name: limonen-10-ol, (+)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid OLE (76.6 mg oleuropein, 14.5 mg hydroxytyrosol)
Study: 23766098
Drug: Capsulated OLE
Normalized name: limonen-10-ol, (+)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsulated OLE (76.6 mg oleuropein, 14.5 mg hydroxytyrosol)
Study: 23766098
Drug: OLE (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: OLE (both formulations)
Study: 19561152
Drug: Spironolactone 25
Normalized name: spironolactone 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone 25 mg o.d.
Study: 15087635
Drug: PCEA with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCEA with 0.1% ropivacaine plus 0.5 microg/ml sufentanil with 6 ml/h background infusion
Study: 15087635
Drug: PCEA with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCEA with 0.1% ropivacaine plus 0.5 microg/ml sufentanil with 9 ml/h background infusion
Study: 15087635
Drug: PCEA with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCEA with 0.1% ropivacaine plus 0.5 microg/ml sufentanil without background infusion
Study: 15087635
Drug: PCEA with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCEA with 0.1% ropivacaine plus 0.5 microg/ml sufentanil (all groups)
Study: 11834229
Drug: One tablet
Normalized name: Hydone Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet of 750 microg levonorgestrel at time -12 h and one tablet at time 0 (Group A)
Study: 11834229
Drug: One tablet
Normalized name: Hydone Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet of 750 microg levonorgestrel at time 0 (Group B)
Study: 11834229
Drug: One tablet
Normalized name: Hydone Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet of 750 microg levonorgestrel at time -24 h and one tablet at time 0 (Group C)
Study: 9926761
Drug: DBM+CS implant
Normalized name: MyoGesic-CS
Approvals — FDA: no, EMA: no, PMDA: no
Description: DBM+CS implant
Study: 8050452
Drug: Dietary supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplementation with 6 g of highly concentrated ethyl esters of EPA and DHA daily for 4 months.
Study: 8050452
Drug: Dietary supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplementation with 6 g of corn oil daily for 4 months (Control).
Study: 3390111
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of thiethylperazine (10 mg) and cimetidine (300 mg)
Study: 3390111
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of thiethylperazine (10 mg), cimetidine (300 mg), and promethazine (25 mg)
Study: 330575
Drug: Single daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single daily intramuscular injection of sisomicin (160 mg)
Study: 330575
Drug: Two daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two daily injections of sisomicin (80 mg)
Study: 21661410
Drug: N‐butyl‐2‐cyanoacrylate injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: N‐butyl‐2‐cyanoacrylate injection
Study: 11740831
Drug: Beta-Blocker therapy
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-Blocker therapy
Study: 10426663
Drug: PALA (1250
Approvals — FDA: no, EMA: no, PMDA: no
Description: PALA (1250 mg/m2 daily x 5 every 4 weeks)
Study: 10426663
Drug: SAM (streptozotocin
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAM (streptozotocin 400 mg/m2 IV daily x 5, doxorubicin 45 mg/m2 IV on day 1 and 22, methyl CCNU 60 mg/m2 orally on days 1 and 22 every 6 weeks)
Study: 16939848
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E supplementation (300 mg twice a day)
Study: 16939848
Drug: Chemotherapy without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy without vitamin E supplementation (Control)
Study: 11916175
Drug: Amoxicillin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (500 mg orally three times per day for 7 days)
Study: 8072200
Drug: UFT (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT (400 mg Tegafur plus 896 mg uracil/day)
Study: 8072200
Drug: FT (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: FT (800 mg/day)
Study: 3178506
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (4.5 g n‐3 PUFA's)
Study: 30616614
Drug: Lesinurad 200
Normalized name: lesinurad 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lesinurad 200 mg plus febuxostat
Study: 30616614
Drug: Lesinurad 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lesinurad 400 mg plus febuxostat
Study: 30616614
Drug: Febuxostat 80
Normalized name: febuxostat 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Febuxostat 80 mg (Control)
Study: 29273063
Drug: Inhaled Nitrous
Normalized name: nitrous oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Nitrous Oxide (N2O) for 1 hour
Study: 29273063
Drug: Fluoxetine (SSRI)
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine (SSRI) after N2O administration
Study: 3356050
Drug: Intravenous meperidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous meperidine 50 mg
Study: 19462722
Drug: Lidocaine 2%
Normalized name: LIDOCAINE 2% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 2% 5 mL periprostatic infiltration
Study: 15103312
Drug: losartan treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: losartan treatment
Study: 15103312
Drug: atenolol treatment
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: atenolol treatment
Study: 12270853
Drug: Clopidogrel (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (300 mg followed by 75 mg daily)
Study: 2403998
Drug: Fluoxetine 60
Normalized name: fluoxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 60 mg/day for 5 weeks
Study: 2403998
Drug: Fluoxetine 20
Normalized name: fluoxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20 mg/day for an additional 5 weeks
Study: 31590702
Drug: Intravenous co-amoxiclav
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous co-amoxiclav (1 g of amoxicillin/200 mg of clavulanic acid)
Study: 28192003
Drug: WEBCARE (online,
Approvals — FDA: no, EMA: no, PMDA: no
Description: WEBCARE (online, 12-weeks fixed, 6 lesson behavioral treatment based on problem solving therapy)
Study: 21252084
Drug: Dexamethasone 0.1%
Normalized name: DEXAMETHASONE 0.1% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 0.1% drops four times daily for 1 week
Study: 21252084
Drug: Hypromellose 0.3%
Normalized name: HYPROMELLOSE 0.3% GEL,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypromellose 0.3% drops four times daily for 1 week
Study: 17762658
Drug: Valsartan 640
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Valsartan 640 mg
Study: 9391542
Drug: Granisetron (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron (3 mg intravenously before chemotherapy)
Study: 9391542
Drug: Ondansetron (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (8 mg intravenously before chemotherapy, then every 8 hours for a total of 3 doses, plus 8 mg oral maintenance every 12 hours for 5 days)
Study: 27836874
Drug: Cardiac resynchronisation
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac resynchronisation therapy (CRT) activated
Study: 27836874
Drug: Cardiac resynchronisation
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac resynchronisation therapy (CRT) not activated
Study: 12634969
Drug: 11C-metomidate PET
Normalized name: metomidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 11C-metomidate PET imaging in group A (patients free of medication)
Study: 12634969
Drug: 11C-metomidate PET
Normalized name: metomidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 11C-metomidate PET imaging in group B (patients on medication)
Study: 12634969
Drug: Medication with
Normalized name: EUGENOL 850 mg in 1 mL DENTAL LIQUID [Walgreens Natural Eugenol/Toothache Medication with cotton pellets and tweezers]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication with adrenal steroid inhibitors and chemotherapy
Study: 9087160
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (200 micrograms aqueous nasal spray, administered twice daily for 2 weeks)
Study: 9087160
Drug: Placebo (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (administered twice daily for 2 weeks)
Study: 17636088
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no fluoxetine)
Study: 8102913
Drug: Topical tiacrilast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tiacrilast 3% hydrogel
Study: 2893778
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg tulobuterol
Study: 2893778
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg salbutamol
Study: 2893778
Drug: Beta 2-agonists
Normalized name: 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN
DrugBank: Hydroxypropyl betadex (DB15379)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta 2-agonists during strong contraction
Study: 2893778
Drug: Continuous beta
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous beta 2-sympathomimetic treatment
Study: 26271221
Drug: Water session
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water session (200 ml water with breakfast, 750 ml water over 2 hours)
Study: 14684712
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Fluoxetine and Nortriptyline)
Study: 11195032
Drug: Isotonic Ems
Normalized name: ISOTON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic Ems salt solution
Study: 9248588
Drug: 1 ml
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml of 50% glycerol
Study: 9248588
Drug: 2 ml
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml of 0.5% bupivacaine
Study: 3499246
Drug: 17/25/1 cold-adapted
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17/25/1 cold-adapted reassortant vaccine
Study: 3499246
Drug: CR 59
Normalized name: Chlorpromazine
DrugBank: Chlorpromazine (DB00477)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CR 59 cold-adapted reassortant vaccine
Study: 24035507
Drug: CPRmeter feedback
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPRmeter feedback device (group G)
Study: 19767092
Drug: Dose-dense paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose-dense paclitaxel (80 mg/m²; 1-h intravenous infusion) plus carboplatin (AUC 6 mg/mL per min) on day 1 of a 21-day cycle; n=312
Study: 19767092
Drug: Conventional regimen:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional regimen: Paclitaxel (180 mg/m²; 3-h intravenous infusion) plus carboplatin (AUC 6 mg/mL per min) on day 1 of a 21-day cycle; n=319
Study: 17224859
Drug: Ultra-low-dose transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-low-dose transdermal estradiol (0.014 mg/d)
Study: 15097957
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of narrowband UVB plus cream PUVA
Study: 15097957
Drug: Cream PUVA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream PUVA
Study: 9525297
Drug: Corticosteroid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid therapy combined with anti-tuberculosis chemotherapy (n=17)
Study: 9525297
Drug: Anti-tuberculosis chemotherapy
Normalized name: Mycobacterium tuberculosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-tuberculosis chemotherapy only (n=17)
Study: 2979691
Drug: Caved-S two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caved-S two tablets twice daily
Study: 2979691
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (Caved-S + Ranitidine)
Study: 2979691
Drug: Post-maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-maintenance therapy
Study: 28958744
Drug: Caregiver worry
Normalized name: GLYCERIN 0.66 mg in 33 mL TOPICAL CREAM [IM SORRY FOR MY SKIN MASK - REVITALIZING]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caregiver worry about medication side effects
Study: 22965298
Drug: JASPER treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: JASPER treatment (30 min, twice weekly for 12 weeks)
Study: 22965298
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (30 h of ABA-based therapy per week)
Study: 16958964
Drug: Regular pattern
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular pattern of trial medication intake
Study: 16958964
Drug: Additional prescribed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional prescribed medication
Study: 1899797
Drug: Oxyquinoline ointment
DrugBank: Oxyquinoline (DB11145)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxyquinoline ointment
Study: 1899797
Drug: Desitin or
Normalized name: Zinc Oxide 40% Topical application Ointment [DESITIN ORIGINAL]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desitin or A & D ointment (Control)
Study: 26351971
Drug: Surfactant (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surfactant (100 mg/kg) and Budesonide (0.25 mg/kg)
Study: 26351971
Drug: Surfactant only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surfactant only (100 mg/kg)
Study: 24457276
Drug: Nicorandil (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil (6 mg bolus injection before PCI and 6 mg/hour infusion for 24 hours)
Study: 11559453
Drug: DRSP/EE (drospirenone
Approvals — FDA: no, EMA: no, PMDA: no
Description: DRSP/EE (drospirenone 3 mg and ethinyl estradiol 30 microg)
Study: 9760324
Drug: Chicken broth
Normalized name: Chicken
DrugBank: Chicken (DB10519)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chicken broth (CB: 109.5 mmol/l Na, 25.3 mmol/l K)
Study: 9760324
Drug: Chicken noodle
Normalized name: Chicken
DrugBank: Chicken (DB10519)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chicken noodle soup (Soup: 333.8 mmol/l Na, 13.7 mmol/l K)
Study: 9760324
Drug: Carbohydrate‐electrolyte drink
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate‐electrolyte drink (CE: 16.0 mmol/l Na, 3.3 mmol/l K)
Study: 7826904
Drug: CMFp (Cyclophosphamide-Methotrexate-Fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMFp (Cyclophosphamide-Methotrexate-Fluorouracil plus low-dose continuous prednisone)
Study: 7826904
Drug: Combined chemoendocrine
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined chemoendocrine therapy (CMFp plus tamoxifen)
Study: 3377464
Drug: Imipenem-cilastatin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem-cilastatin (500 mg each) administered intravenously
Study: 3377464
Drug: Imipenem-cilastatin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem-cilastatin (500 mg each) administered intraperitoneally
Study: 31233464
Drug: Bortezomib (1.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib (1.3 mg/m/dose)
Study: 19235866
Drug: High-dose interferon-alpha-2b
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose interferon-alpha-2b (10 MU) with ribavirin (RBV)
Study: 19235866
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose interferon-alpha-2b (6 MU) with ribavirin (RBV)
Study: 15961759
Drug: MEC plus
Normalized name: Ivomec Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEC plus lintuzumab (12 mg/m2)
Study: 8749876
Drug: Isoproterenol administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoproterenol administration during tilt test
Study: 2702512
Drug: Inhaled lignocaine
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled lignocaine (40 mg)
Study: 139671
Drug: Stanozolol (an
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stanozolol (an anabolic steroid), orally active, duration 4 months
Study: 28031707
Drug: Budesonide/formoterol (B/F)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol (B/F) 320/9 μg, twice daily
Study: 19371522
Drug: Intravenous octreotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous octreotide (100 microg)
Study: 16896118
Drug: Levamisole (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levamisole (administered bimonthly)
Study: 11491177
Drug: Influenza vaccines
Normalized name: Influenza vaccines
Approvals — FDA: no, EMA: no, PMDA: no
Description: Influenza vaccines (split product and surface antigen vaccines)
Study: 11491177
Drug: Antiviral drugs
Normalized name: antiviral drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiviral drugs (amantadine and rimantadine)
Study: 11491177
Drug: New antiviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: New antiviral agents targeting influenza neuraminidase
Study: 9396433
Drug: Nadroparin (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadroparin (0.6 mL of 10,250 anti-Xa IU/mL)